Patterns of relapse and modalities of treatment of breast cancer

The 'IRIS' project, a multicenter observational study

M. Cazzaniga, P. Pronzato, S. L. Leto Di Priolo, A. De Matteis, F. Di Costanzo, R. Passalacqua, R. Rosso, V. Torri

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: The aim of this study was to describe the patterns of breast cancer relapse and the factors influencing therapeutic choices in an unselected postmenopausal population. Methods: Five hundred and thirty-nine patients were enrolled between October 1999 and March 2001. The majority (92.6%) underwent surgery for the primary tumor: there was no difference between general and university hospitals in terms of the type of mastectomy, but a slight difference was found between Southern and Northern Centers. Results: At the time of first relapse, 61.6% of the patients had a good Karnofsky performance status. The median disease-free interval (DFI) was 34 months. More than half of the patients (62.3%) presented a single metastasis. Metastatic disease was treated with chemotherapy in 64.8% of cases (alone in 44.1%, and in combination with hormone therapy in 20.1%), hormone therapy alone was given in 30.8% of cases. The main reasons for choosing chemotherapy were age (31%), standard guidelines (19.4%) and the site of metastatic disease (14.3%), and those for selecting hormone therapy were age (26.6%), site of relapse (19.3%), standard guidelines (19.2%), biological tumor characteristics (14.3%) and the DFI (11.1%). Taxane-containing treatments accounted for 46.1% of the chemotherapies, whereas letrozole was the preferred hormone (41.2%). Conclusion: The first relapse of breast cancer is often single, at bone or viscera, and mainly diagnosed by instrumental screening examinations. The preferred chemo-and hormone therapies are taxane-containing regimens and letrozole, respectively.

Original languageEnglish
Pages (from-to)260-268
Number of pages9
JournalOncology
Volume66
Issue number4
DOIs
Publication statusPublished - 2004

Fingerprint

Multicenter Studies
Observational Studies
letrozole
Breast Neoplasms
Recurrence
Hormones
Drug Therapy
Therapeutics
Guidelines
Karnofsky Performance Status
Viscera
Mastectomy
General Hospitals
Neoplasms
Neoplasm Metastasis
Bone and Bones
Population
taxane

Keywords

  • Breast cancer
  • Follow-up
  • Relapse

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Patterns of relapse and modalities of treatment of breast cancer : The 'IRIS' project, a multicenter observational study. / Cazzaniga, M.; Pronzato, P.; Leto Di Priolo, S. L.; De Matteis, A.; Di Costanzo, F.; Passalacqua, R.; Rosso, R.; Torri, V.

In: Oncology, Vol. 66, No. 4, 2004, p. 260-268.

Research output: Contribution to journalArticle

Cazzaniga, M, Pronzato, P, Leto Di Priolo, SL, De Matteis, A, Di Costanzo, F, Passalacqua, R, Rosso, R & Torri, V 2004, 'Patterns of relapse and modalities of treatment of breast cancer: The 'IRIS' project, a multicenter observational study', Oncology, vol. 66, no. 4, pp. 260-268. https://doi.org/10.1159/000078325
Cazzaniga, M. ; Pronzato, P. ; Leto Di Priolo, S. L. ; De Matteis, A. ; Di Costanzo, F. ; Passalacqua, R. ; Rosso, R. ; Torri, V. / Patterns of relapse and modalities of treatment of breast cancer : The 'IRIS' project, a multicenter observational study. In: Oncology. 2004 ; Vol. 66, No. 4. pp. 260-268.
@article{86f65836b88247a0b832a7e97739417e,
title = "Patterns of relapse and modalities of treatment of breast cancer: The 'IRIS' project, a multicenter observational study",
abstract = "Objectives: The aim of this study was to describe the patterns of breast cancer relapse and the factors influencing therapeutic choices in an unselected postmenopausal population. Methods: Five hundred and thirty-nine patients were enrolled between October 1999 and March 2001. The majority (92.6{\%}) underwent surgery for the primary tumor: there was no difference between general and university hospitals in terms of the type of mastectomy, but a slight difference was found between Southern and Northern Centers. Results: At the time of first relapse, 61.6{\%} of the patients had a good Karnofsky performance status. The median disease-free interval (DFI) was 34 months. More than half of the patients (62.3{\%}) presented a single metastasis. Metastatic disease was treated with chemotherapy in 64.8{\%} of cases (alone in 44.1{\%}, and in combination with hormone therapy in 20.1{\%}), hormone therapy alone was given in 30.8{\%} of cases. The main reasons for choosing chemotherapy were age (31{\%}), standard guidelines (19.4{\%}) and the site of metastatic disease (14.3{\%}), and those for selecting hormone therapy were age (26.6{\%}), site of relapse (19.3{\%}), standard guidelines (19.2{\%}), biological tumor characteristics (14.3{\%}) and the DFI (11.1{\%}). Taxane-containing treatments accounted for 46.1{\%} of the chemotherapies, whereas letrozole was the preferred hormone (41.2{\%}). Conclusion: The first relapse of breast cancer is often single, at bone or viscera, and mainly diagnosed by instrumental screening examinations. The preferred chemo-and hormone therapies are taxane-containing regimens and letrozole, respectively.",
keywords = "Breast cancer, Follow-up, Relapse",
author = "M. Cazzaniga and P. Pronzato and {Leto Di Priolo}, {S. L.} and {De Matteis}, A. and {Di Costanzo}, F. and R. Passalacqua and R. Rosso and V. Torri",
year = "2004",
doi = "10.1159/000078325",
language = "English",
volume = "66",
pages = "260--268",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Patterns of relapse and modalities of treatment of breast cancer

T2 - The 'IRIS' project, a multicenter observational study

AU - Cazzaniga, M.

AU - Pronzato, P.

AU - Leto Di Priolo, S. L.

AU - De Matteis, A.

AU - Di Costanzo, F.

AU - Passalacqua, R.

AU - Rosso, R.

AU - Torri, V.

PY - 2004

Y1 - 2004

N2 - Objectives: The aim of this study was to describe the patterns of breast cancer relapse and the factors influencing therapeutic choices in an unselected postmenopausal population. Methods: Five hundred and thirty-nine patients were enrolled between October 1999 and March 2001. The majority (92.6%) underwent surgery for the primary tumor: there was no difference between general and university hospitals in terms of the type of mastectomy, but a slight difference was found between Southern and Northern Centers. Results: At the time of first relapse, 61.6% of the patients had a good Karnofsky performance status. The median disease-free interval (DFI) was 34 months. More than half of the patients (62.3%) presented a single metastasis. Metastatic disease was treated with chemotherapy in 64.8% of cases (alone in 44.1%, and in combination with hormone therapy in 20.1%), hormone therapy alone was given in 30.8% of cases. The main reasons for choosing chemotherapy were age (31%), standard guidelines (19.4%) and the site of metastatic disease (14.3%), and those for selecting hormone therapy were age (26.6%), site of relapse (19.3%), standard guidelines (19.2%), biological tumor characteristics (14.3%) and the DFI (11.1%). Taxane-containing treatments accounted for 46.1% of the chemotherapies, whereas letrozole was the preferred hormone (41.2%). Conclusion: The first relapse of breast cancer is often single, at bone or viscera, and mainly diagnosed by instrumental screening examinations. The preferred chemo-and hormone therapies are taxane-containing regimens and letrozole, respectively.

AB - Objectives: The aim of this study was to describe the patterns of breast cancer relapse and the factors influencing therapeutic choices in an unselected postmenopausal population. Methods: Five hundred and thirty-nine patients were enrolled between October 1999 and March 2001. The majority (92.6%) underwent surgery for the primary tumor: there was no difference between general and university hospitals in terms of the type of mastectomy, but a slight difference was found between Southern and Northern Centers. Results: At the time of first relapse, 61.6% of the patients had a good Karnofsky performance status. The median disease-free interval (DFI) was 34 months. More than half of the patients (62.3%) presented a single metastasis. Metastatic disease was treated with chemotherapy in 64.8% of cases (alone in 44.1%, and in combination with hormone therapy in 20.1%), hormone therapy alone was given in 30.8% of cases. The main reasons for choosing chemotherapy were age (31%), standard guidelines (19.4%) and the site of metastatic disease (14.3%), and those for selecting hormone therapy were age (26.6%), site of relapse (19.3%), standard guidelines (19.2%), biological tumor characteristics (14.3%) and the DFI (11.1%). Taxane-containing treatments accounted for 46.1% of the chemotherapies, whereas letrozole was the preferred hormone (41.2%). Conclusion: The first relapse of breast cancer is often single, at bone or viscera, and mainly diagnosed by instrumental screening examinations. The preferred chemo-and hormone therapies are taxane-containing regimens and letrozole, respectively.

KW - Breast cancer

KW - Follow-up

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=3042588089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042588089&partnerID=8YFLogxK

U2 - 10.1159/000078325

DO - 10.1159/000078325

M3 - Article

VL - 66

SP - 260

EP - 268

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -